more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.15 USD

+0.21 (0.28%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

Top 29% (72 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research Published on April 16,2020

Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

HAEPositive Net Change

Haemonetics (HAE) Buys enicor to Expand Testing Portfolio

by Zacks Equity Research Published on April 06,2020

Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.

medical

Medtronic's Evolut TAVR System Shows Positive Study Results

by Zacks Equity Research Published on March 30,2020

Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.

medical

Haemonetics (HAE) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research Published on March 30,2020

Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HAEPositive Net Change

Allscripts' Veradigm Business Line Unveils New Solution

by Zacks Equity Research Published on March 09,2020

Allscripts' (MDRX) Veradigm business line introduces new solution that will drive growing medication adherence and improve patient care.

medical

Why Is Haemonetics (HAE) Down 8.4% Since Last Earnings Report?

by Zacks Equity Research Published on March 05,2020

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HAEPositive Net Change

Haemonetics (HAE): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research Published on March 03,2020

Haemonetics (HAE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

HAEPositive Net Change

medical

Here's Why You Should Retain Haemonetics in Your Portfolio Now

by Zacks Equity Research Published on February 18,2020

Haemonetics (HAE) witnesses high investor confidence on solid prospects.

medical

Here's Why You Should Add Hill-Rom to Your Portfolio Now

by Zacks Equity Research Published on February 11,2020

Investor confidence is at a high, thanks to Hill-Rom (HRC) solid prospects.

medical

Has Haemonetics (HAE) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on February 07,2020

Is (HAE) Outperforming Other Medical Stocks This Year?

HAEPositive Net Change

Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand

by Zacks Equity Research Published on February 05,2020

Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.

Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on February 04,2020

Haemonetics (HAE) delivered earnings and revenue surprises of 23.68% and 2.29%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

HAEPositive Net Change

Haemonetics (HAE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research Published on January 28,2020

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HAEPositive Net Change

New Alliances Aid Quest Diagnostics Despite Reimbursement Woes

by Urmimala Biswas Published on January 27,2020

Quest Diagnostics (DGX) is currently concentrating on diagnostic information services arm and disciplined capital deployment.

medical

New Product Suite Boosts Intersect ENT Despite Cost Concerns

by Zacks Equity Research Published on January 23,2020

With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.

medical

Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?

by Zacks Equity Research Published on January 23,2020

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.

medical

Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark

by Zacks Equity Research Published on January 22,2020

We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.

Zimmer Biomet Rides on Product Launches Despite Pricing Woes

by Zacks Equity Research Published on January 22,2020

Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.

medical

Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block

by Zacks Equity Research Published on January 22,2020

Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.

medical

Hill-Rom (HRC) Gains Ground on Global Expansion, New Menu

by Zacks Equity Research Published on January 21,2020

Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.